-

Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes.

As previously announced, in light of Hologic’s pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
Release Versions
English
$Cashtags
$HOLX
Hashtags
#earnings
#holx

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIN
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab...

Hologic Signs Definitive Agreement to Acquire Reveal Genomics

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Revea...

More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram

MARLBOROUGH, Mass.--(BUSINESS WIRE)--More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram Based on a New Survey of 1,000 Women...
Back to Newsroom